Compare Recursion Pharmaceuticals Inc (RXRX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while ZIM Integrated Shipping Services Ltd trades at $29.99 (market cap $3.65B). The key difference: ZIM Integrated Shipping Services Ltd is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| RXRX | ZIM | |
|---|---|---|
Market Cap | $2.14B | $3.65B |
Volume | 30,789,535 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $6.79 | $30.51 |
52-Week Low | $2.84 | $12.44 |
Typical Hold Time | 23 Days | 27 Days |
Enterprise Value | $1.66B | $7.32B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
ZIM Integrated Shipping Services trades at $30.26, up 0.9% today and near its 52-week high of $30.96. The stock shows bullish technical momentum with strong moving average signals, though RSI indicators suggest potential overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with $0.53 EPS versus -$0.02 expected, driven by 9% revenue growth to $1.8 billion. The company faces acquisition uncertainty with Hapag-Lloyd's $35 per share offer pending Israeli government approval.
Investment outlook remains mixed with strong operational performance offset by merger uncertainty. The stock trades at attractive valuations (P/S 0.57, P/B 0.94) but faces headwinds from declining 2026 profit margins (2.15% vs 6.94% in 2025). Analyst consensus leans cautious with 67% hold ratings, while technical indicators suggest near-term resistance at current levels. Key risks include government approval of acquisition and volatile shipping rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
